cyclotropium: Cleavage of the ciclotropium ester bond results in the formation of alpha-phenylciclopentylacetic acid; N-isopropyltropinium is a metabolite; [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 15030364 |
| SCHEMBL ID | 917336 |
| MeSH ID | M0119587 |
| Synonym |
|---|
| cyclotropium |
| 85166-20-7 |
| ciclotropium bromide |
| bromure de ciclotropium |
| bromure de ciclotropium [french] |
| bromuro de ciclotropio |
| unii-vnc65mex24 |
| ciclotropium bromide [inn] |
| bromuro de ciclotropio [spanish] |
| vnc65mex24 , |
| ciclotropii bromidum |
| cyclotropium bromide |
| (8r)-3alpha-hydroxy-8-isopropyl-1alphah,5alphah-tropanium bromide, alpha-phenylcyclopentaneacetate |
| ciclotropii bromidum [latin] |
| (8r)-3.alpha.-hydroxy-8-isopropyl-1.alpha.h,5.alpha.h-tropanium bromide, .alpha.-phenylcyclopentaneacetate |
| 8-azoniabicyclo(3.2.1)octane, 3-((2-cyclopentyl-2-phenylacetyl)oxy)-8-methyl-8-(1-methylethyl)-, bromide (1:1), (3-endo,8-syn)- |
| ciclotropium bromide [mart.] |
| ciclotropiumbromid |
| SCHEMBL917336 |
| Q27291915 |
| [(1s,5r)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-cyclopentyl-2-phenylacetate;bromide |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The relevance of this metabolic route for ciclotropium bromide (HIT-PCE, CAS 85166-20-7) including its stereochemical aspects was studied in a preliminary pharmacokinetic study." | ( Studies on the metabolic clearance of ciclotropium to alpha-phenylciclopentylacetic acid using a new enantiospecific metabolite assay. Liebmann, B; Mayer, S; Mutschler, E; Spahn-Langguth, H, 1992) | 0.28 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (57.14) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.01) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (42.86%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (57.14%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||